体液微小RNA在胆管癌诊断中的研究进展

doi:10.3760/cma.j.issn.1673422X.2017.04.016

摘要/Abstract

摘要： 胆管癌发展慢但转移性极高，被发现时往往已错过最佳手术期，目前缺乏有效的诊断指标。近年来，随着分子生物学的飞速发展，研究发现微小RNA与胆管癌关系密切。由于微小RNA在各种类型的体液中有很大的稳定性，所以血清/血浆及胆汁中的微小RNA均有望成为胆管癌诊断中的潜在生物标志物。

关键词: 微RNAs, 胆管肿瘤, 血清, 血浆, 胆汁, 诊断

Abstract: The development of cholangiocarcinoma is slow, but its metastasis is extremely quick. When the tumor is found, the patients often have missed optimal operation period, and there is a lack of effective diagnostic indexes at present. In recent years, with the rapid development of molecular biology, studies find that microRNAs (miRNAs) are closely associated with cholangiocarcinoma. Because of miRNAs have great stability in various types of body fluids, so miRNAs in serum/plasma and bile are expected to become potential biomarkers in the diagnosis of cholangiocarcinoma.

Key words: MicroRNAs, Bile duct neoplasms, Serum, Plasma, Bile, Diagnosis

邹荣基,马庆久. 体液微小RNA在胆管癌诊断中的研究进展[J]. 国际肿瘤学杂志, 2017, 44(4): 300-303.

Zou Rongji, Ma Qingjiu. Research progress on body fluids microRNAs in the diagnosis of cholangiocarcinoma[J]. Journal of International Oncology, 2017, 44(4): 300-303.

参考文献

［1］刘子沛, 郑燕华, 白洁, 等. 多种肿瘤标志物检测在胆管癌诊断中的临床意义［J］. 中华肝胆外科杂志, 2013, 19(9): 657-660. DOI: 10.3760/cma.j.issn.10078118.2013.09.005. ［2］ Hwang J, Kim YK, Park MJ, et al. Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI［J］. J Magn Reson Imaging, 2012, 36(4): 881-889. DOI: 10.1002/jmri.23728. ［3］ Motawi TK, Rizk SM, Ibrahim TM, et al. Circulating microRNAs, miR-92a, miR-100 and miR-143, as non-invasive biomarkers for bladder cancer diagnosis［J］. Cell Biochem Funct, 2016, 34(3): 142-148. DOI: 10.1002/cbf.3171. ［4］ Bertoli G, Cava C, Castiglioni I. MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer［J］. Theranostics, 2015, 5(10): 1122-1143. DOI: 10.7150/thno.11543. ［5］ Braicu C, Cojocneanu-Petric R, Chira S, et al. Clinical and pathological implications of miRNA in bladder cancer［J］. Int J Nanomedicine, 2015, 10: 791-800. DOI: 10.2147/IJN.S72904. ［6］ Fujita Y, Kuwano K, Ochiya T, et al. The impact of extracellular vesicle-encapsulated circulating microRNAs in lung cancer research［J］. Biomed Res Int, 2014, 2014: 486413. DOI: 10.1155/2014/486413. ［7］ Li L, Masica D, Ishida M, et al. Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis［J］. Hepatology, 2014, 60(3): 896-907. DOI: 10.1002/hep.27050. ［8］ Plieskatt J, Rinaldi G, Feng Y, et al. A microRNA profile associated with opisthorchis viverrini-induced cholangiocarcinoma in tissue and plasma［J］. BMC Cancer, 2015, 15: 309. DOI: 10.1186/s12885-015-1270-5. ［9］ Liang Z, Liu X, Zhang Q, et al. Diagnostic value of microRNAs as biomarkers for cholangiocarcinoma［J］. Dig Liver Dis, 2016, 48(10): 1227-1232. DOI: 10.1016/j.dld.2016.07.006. ［10］ Meng F, Henson R, Lang M, et al. Involvement of human microRNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines［J］. Gastroenterology, 2006, 130(7): 2113-2129. DOI: 10.1053/j.gastro.2006.02.057. ［11］ Silakit R, Loilome W, Yongvanit P, et al. Circulating miR-192 in liver fluke-associated cholangiocarcinoma patients: a prospective prognostic indicator［J］. J Hepatobiliary Pancreat Sci, 2014, 21(12): 864-872. DOI: 10.1002/jhbp.145. ［12］彭丰, 王敏, 江建新, 等. 微RNA-200b在胆管癌中的表达及其对癌细胞凋亡与侵袭转移特性的影响［J］. 中华肝胆外科杂志, 2014, 20(2): 123-127. DOI: 10.3760/cma.j.issn.1007-8118.2014.02.012. ［13］ Huang M, Wu X, Cao H, et al. Regulatory role of serum miR-224 in invasiveness and metastasis of cholangiocarcinoma［J］. Zhonghua Gan Zang Bing Za Zhi, 2015, 23(10): 748-753. DOI: 10.3760/cma.j.issn.1007-3418.2015.10.008. ［14］ Kojima M, Sudo H, Kawauchi J, et al. MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers［J］. PLoS One, 2015, 10(2): e0118220. DOI: 10.1371/journal.pone.0118220. ［15］ Cheng Q, Feng F, Zhu L, et al. Circulating miR-106a is a novel prognostic and lymph node metastasis indicator for cholangiocarcinoma［J］. Sci Rep, 2015, 5: 16103. DOI: 10.1038/srep16103. ［16］ Razumilava N, Gores GJ. Cholangiocarcinoma［J］. Lancet, 2014, 383(9935): 2168-2179. DOI: 10.1016/S0140-6736(13)61903-0. ［17］ Wang S, Yin J, Li T, et al. Upregulated circulating miR-150 is associated with the risk of intrahepatic cholangiocarcinoma［J］. Oncol Rep, 2015, 33(2): 819-825. DOI: 10.3892/or.2014.3641. ［18］ Huang S, Chen Y, Wu W, et al. miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor［J］. PLoS One, 2013, 8(12): e80707. DOI: 10.1371/journal.pone.0080707. ［19］ míd D, Kubaková D, Dole-al J, et al. Predictive and prognostic factors of gastric cancer［J］. Rozhl Chir, 2016, 95(4): 156-161. ［20］ Feng J, Yang Y, Zhang P, et al. miR-150 functions as a tumour suppressor in human colorectal cancer by targeting c-Myb［J］. J Cell Mol Med, 2014, 18(10): 2125-2134. DOI: 10.1111/jcmm.12398. ［21］ Qu Y, Pan S, Kang M, et al. MicroRNA-150 functions as a tumor suppressor in osteosarcoma by targeting IGF2BP1［J］. Tumour Biol, 2016, 37(4): 5275-5284. DOI: 10.1007/s13277-015-4389-8. ［22］ Huang Y, Yang YB, Zhang XH, et al. MicroRNA-21 gene and cancer［J］. Med Oncol, 2013, 30(1): 376. DOI: 10.1007/s12032-012-0376-8. ［23］ Kishimoto T, Eguchi H, Nagano H, et al. Plasma miR-21 is a novel diagnostic biomarker for biliary tract cancer［J］. Cancer Sci, 2013, 104(12): 1626-1631. DOI: 10.1111/cas.12300. ［24］ Correa-Gallego C, Maddalo D, Doussot A, et al. Circulating plasma levels of microRNA-21 and microRNA-221 are potential diagnostic markers for primary intrahepatic cholangiocarcinoma［J］. PLoS One, 11(9): e0163699. DOI: 10.1371/journal.pone.0163699. ［25］ Pasternak A, Szura M, Gil K, et al. Metabolism of bile with respect to etiology of gallstone disease-systematic review［J］. Folia Med Cracov, 2014, 54(2): 5-16. ［26］ Munoz-Garrido P, García-Fernández de Barrena M, Hijona E, et al. MicroRNAs in biliary diseases［J］. World J Gastroenterol, 2012, 18(43): 6189-6196. DOI: 10.3748/wjg.v18.i43.6189. ［27］ Haga H, Yan I, Takahashi K, et al. Emerging insights into the role of microRNAs in the pathogenesis of cholangiocarcinoma［J］. Gene Expr, 2014, 16(2): 93-99. DOI: 10.3727/105221614X13919976902174. ［28］ Shigehara K, Yokomuro S, Ishibashi O, et al. Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer［J］. PLoS One, 2011, 6(8): e23584. DOI: 10.1371/journal.pone.0023584. ［29］ Voigtl-nder T, Gupta SK, Thum S, et al. MicroRNAs in serum and bile of patients with primary sclerosing cholangitis and/or cholangiocarcinoma［J］. PLoS One, 2015, 10(10): e0139305. DOI: 10.1371/journal.pone.0139305. ［30］ Bernuzzi F, Marabita F, Lleo A, et al. Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma［J］. Clin Exp Immunol, 2016, 185(1): 61-71. DOI: 10.1111/cei.12776. ［31］ Shen J, Stass SA, Jiang F. MicroRNAs as potential biomarkers in human solid tumors［J］. Cancer Lett, 2013, 329(2): 125-136. DOI: 10.1016/j.canlet.2012.11.001. ［32］ Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review［J］. EMBO Mol Med, 2012, 4(3): 143159. DOI: 10.1002/emmm.201100209. ［33］ YáezMó M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions［J］. J Extracell Vesicles, 2015, 4: 27066. DOI: 10.3402/jev.v4.27066.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[3]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[4]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[5]	陈琦, 徐晨阳, 王寅, 雷大鹏. 高光谱成像在头颈部肿瘤诊疗中的应用现状[J]. 国际肿瘤学杂志, 2024, 51(5): 298-302.
[6]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[7]	张丽丽, 谭茹, 房雪利, 杨宇, 桑铮, 李宝生. 乳腺导管原位癌影像学诊断、病理学升级及影像学技术进展[J]. 国际肿瘤学杂志, 2024, 51(3): 166-169.
[8]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[9]	龚艳, 陈洪雷. 微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[10]	李丹, 李睿尧, 李膺函, 于秀艳, 吴雪峰. 血清miR-19b、miR-744-5p水平在非小细胞肺癌诊断中的临床价值[J]. 国际肿瘤学杂志, 2024, 51(2): 83-88.
[11]	金旭东, 陈忠坚, 毛伟敏. MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[12]	黄镇, 陈永顺. 循环肿瘤DNA在肝细胞癌诊疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(1): 59-64.
[13]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[14]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[15]	鞠逸凡, 徐晨阳, 雷大鹏. 病理组学在头颈部肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 294-298.